Perrigo Company has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals.
Acknowledging strong public skepticism in Europe over free trade talks with the U.S., the...
Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered...
Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.
The company creates DNA-based vaccines and immune therapies, and said its vaccine might be able to address a variety of developing strains of Ebola. Inovio said that it will work with GeneOne Life Science, a company in which Inovio owns a minority stake.
Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts.
The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.
Genzyme, a Sanofi company, today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness.
Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.''
Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease (PD).
An environment of increasing risks, complex regulations and continuing cost pressures is impeding healthcare executives from moving quickly to seize untapped industry opportunities, according to the 7th annual UPS "Pain in the (Supply) Chain" survey.
Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.
Navidea Biopharmaceuticals today announced the receipt of an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.67 million from the National Cancer Institute (NCI), National Institutes of Health (NIH), to fund evaluation of Lymphoseek ® (technetium Tc 99m tilmanocept) Injection in women with cervical cancer.
As the global market for drugs surpasses $1 trillion this year, growing payer scrutiny of value for money is just one of the factors that will drive disruptive change in the use of medicines over the next decade, according to a report issued today by the IMS Institute for Healthcare Informatics.
The Obama administration's decision to curb the ability of U.S. corporations to skirt taxes by merging with foreign companies kicked off an immediate election-season debate over when and how to tackle the nation's complex corporate tax code.
ACCESS Pharmaceuticals has signed an exclusive, global license agreement with Plasma Technologies for the development and commercialization of its proprietary plasma fractionation process. Concurrently, the company announced a new corporate management team and its intention to strategically refocus and rebrand the company as PlasmaTech Biopharmaceuticals.
Lannett Company today announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at Average Wholesale Price (AWP) were approximately $43M.
Silarus Therapeutics and Thyritope Biosciences each will receive up to $10M in Series A financing and R&D support from Avalon Ventures and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, the community of innovation established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.
Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.
Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.
The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.
A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. China's official Xinhua News Agency said Briton Mark Reilly and his Chinese co-defendants were given a three-year reprieve at their sentencing Friday.
Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, are announcing a strategic R&D agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.
German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The Leverkusen-based company that invented aspirin said Thursday the move would be part of an effort to focus the group on its health care and crop science businesses.
Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.
The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.
EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.
Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.
- Page 1